Get in touch today 206.598.4100 or

Schedule an Appointment

Tyler Gutschenritter, MD

Overview

Tyler Gutschenritter grew up in Wichita, Kansas and left home to attend the University of Tulsa followed by the University of Oklahoma School of Community Medicine. His interests in radiation oncology are SRS, SBRT/SABR, and particle therapy with disease site interests in GI & GU. He also has interests in leadership and clinical administration with a focus in workflow optimization utilizing IT/EMR integration of radiation oncology specific needs and metrics in order to improve clinical efficiency and multidisciplinary care delivery. Outside of work, he enjoys hanging out with his wife, hiking, traveling, weightlifting, playing golf and basketball, and always looking for the best food, drinks, and coffee in Seattle.

 

Education and Training

College: University of Tulsa, Tulsa, OK; Biochemistry

Medical School: University of Oklahoma College of Medicine, Oklahoma City, OK

Preliminary year: Internal Medicine, OU School of Community Medicine Tulsa, Oklahoma

Published works

Gutschenritter T, Venur VA, Combs SE, Vellayappan B, Patel AP, Foote M, Redmond KJ, Wang TJC, Sahgal A, Chao ST, Suh JH, Chang EL, Ellenbogen RG, Lo SS. The judicious use of stereotactic radiosurgery and hypofractionated stereotactic radiotherapy in the management of large brain metastases.  Cancers (Basel). 2020 December 29; 13(1):70.

Ludmir EB, Gutschenritter T, Pinnix CC, Gunther JR, Nastoupil LJ, Khoury JD, Medeiros LJ Dabaja BS, Milgrom SA. Coincident Primary Breast Lymphoma and Gastrointestinal Stromal Tumor: Case Series and Molecular Mechanisms. Onco Targets Ther. 2018. Dec 10;11:8937-8942

Gutschenritter T, Machiorlatti M, Vesely S, Ahmad B, Razaq W, Razaq M. Outcomes and prognostic factors of resected salivary gland malignancies: Examining a single institution’s 12-year experience. Anticancer Res. 2017 Sep;37(9):5019-5025.

Gutschenritter T, Matthiesen C, Razaq M. Protracted Lhermitte sign following cisplatin and intensity modulated radiation therapy for nasopharyngeal carcinoma. American Journal of Therapeutics. 2017 Feb 17.

Gutschenritter T, Zhao L, Matthiesen C, Razaq W, Razaq M. Concurrent colon adenocarcinoma and hepatoid lung adenocarcinoma with normal serum level and negative immunostain of alpha-fetoprotein. Clinical Case Reports and Reviews. 2016, 2(3): 366-368.

Bedford, R.; LePage, D.; Hoffmann, R.; Kennedy, S.; Gutschenritter, T.; Bull, L.; Sujijantarat, N.; DiCesare, J.C.; Sheaff, R.J. Luciferase Inhibition by a Novel Naphthoquinone. J. Photochem. Photobiol. B [Online] 2012, 107, pp.55-64.